Cassava Sciences Inc vs iShares Core MSCI Emerging Markets ETF — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while iShares Core MSCI Emerging Markets ETF trades at $81.11. The key difference: iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | IEMG | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $86.00 |
52-Week Low | $0.87 | $61.76 |
Enterprise Value | -$34.93M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
IEMG trades at $80.97, up 1.77% with a bullish technical signal from moving averages. The ETF offers emerging markets exposure with a 0.09% expense ratio and significant technology weighting. Recent performance shows strong returns but elevated volatility compared to developed market alternatives.
The outlook remains positive given attractive valuations and growth potential in emerging markets, though concentration in tech/AI stocks and geopolitical risks warrant monitoring. Current technical indicators show potential resistance near $81 with support at $79-80 levels.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →